Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

IMS 2023 | Improving manufacturing of CAR-T cells in multiple myeloma: PHE885 & other novel constructs

Andrew Cowan • 29 Sep 2023

IMS 2023

Multiple Myeloma CAR-T Ciltacabtagene autoleucel PHE885

In this video, Andrew Cowan, MD, Fred Hutchinson Cancer Center, Seattle, WA, briefly discusses the importance of improving the manufacturing of BCMA-directed CAR-T cells in multiple myeloma, and further highlights the promising preliminary results observed with the use of PHE885. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Consulting: BMS, Adaptive
Research funding: BMS, Janssen, Adaptive, Harpoon, AbbVie, Sanofi, Nektar

Novel targets being explored in multiple myeloma and the value of CELMoDs

Andrew Cowan • 29 Sep 2023

Phase I trial evaluating a gamma secretase inhibitor in combination with CAR-T cells in R/R myeloma

Andrew Cowan • 29 Sep 2023

Real-world analysis of patients with R/R myeloma treated with lenalidomide & an anti-CD38 mAb

Andrew Cowan • 29 Sep 2023

First-in-human: BCMA CAR-T plus gamma secretase inhibitor in R/R myeloma

Andrew Cowan • 11 Dec 2021

Related Videos

MRD Focus: why measurable residual disease testing is the future

Bruno Paiva et al. • 16 Aug 2018

Myeloma 2016: Panel discussion on the application of genomics studies

Leif Bergsagel et al. • 14 Jun 2016

Overview of the SIRIUS clinical trial in the treatment of multiple myeloma

Maria-Victoria Mateos • 29 Jan 2016

New targets in relapsed/refractory multiple myeloma patients

Sagar Lonial • 22 Jun 2017